전체 프로그램

ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved139 programs
CGTLimited DatastaleBeijing BiotechPhase 2

DLL3/CD56 CAR-NK cells (EB-DART-NK01, EB-DART-NK01 (DLL3/CD56 CAR-NK cells))

Small Cell Lung Cancer (SCLC); Relapsed/Refractory SCLC · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleJuno Therapeutics, Inc., a Bris…Phase 1

EGFRt/19-28z/4-1BBL CAR T cells (EGFRt/19-28z/4-1BBL CAR T cells)

Chronic Lymphocytic Leukemia (CLL); Relapsed · EGFR

#EGFR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleSolving Kids' CancerPhase 1

Ex vivo Expanded and Activated Haploidentical Donor NK Cells (Ex vivo Expanded and Activated Haploidentical Donor NK Cells)

Neuroblastoma; Relapsed Neuroblastoma · Neuroblastoma

#Neuroblastoma#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Discontinued
CGTLimited DatastaleBeijing GoBroad HospitalPhase 1

FL33-03 CAR-T therapy (FL33-03 CAR-T therapy)

Refractory/Relapsed Acute Myeloid Leukaemia · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleHe HuangPhase 2

GC022F CAR-T cells (GC022F CAR-T cells)

Relapsed and Refractory; Lymphoid Hematological Malignancies · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleSinobioway Cell Therapy Co., Lt…Preclinical

GD2-targeted CAR-T cells (GD2-targeted CAR-T cells)

Relapsed or Refractory Neuroblastoma · FRα

#FR#CGT#Preclinical#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleNationwide Children's HospitalPhase 2

GEM/DOX + TGFBi expanded NK cells (GEM/DOX + TGFBi expanded NK cells)

Pediatric Sarcoma, Refractory; Pediatric Sarcoma, Relapsed · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleChinese PLA General HospitalPhase 1

GoFast CD19 CAR T Cells (GoFast CD19 CAR T Cells)

Relapsed or Refractory Large B-cell Lymphoma · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleDonghua ZhangPreclinical

Infusion of BAFFR CAR-T therapy for relapsed/refractory B-cell malignancies (Infusion of BAFFR CAR-T therapy for relapsed/refractory B-cell malignancies)

Relapsed/Refractory B-cell Malignancies · FRα

#FR#CGT#Preclinical#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
AntibodyLimited DatastaleSun Yat-sen UniversityPhase 2

Ivonescimab Combined With Chemotherapy (Ivonescimab Combined With Chemotherapy)

Relapsed or Metastatic Thymic Cancer; First-line Treatment · Relapsed or Metastatic Thymic Cancer

#RelapsedorMetastaticThymicCancer#Antibody#Phase2#monoclonal-antibody#First-lineTreatment+1
Trials 1Status Recruiting
CGTLimited DatastaleNanjing Legend Biotech Co.Phase 1

LCAR-B4822M CAR-T Cell Immunotherapy (LCAR-B4822M CAR-T Cell Immunotherapy)

Refractory or Relapsed Multiple Myeloma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleNanjing Legend Biotech Co.Phase 1

LUCAR-20SP cells (LUCAR-20SP cells)

Relapsed B-cell Non-Hodgkin Lymphoma; Refractory B-cell Non-Hodgkin Lymphoma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleNanjing Legend Biotech Co.Phase 1

LUCAR-G79 T cells (LUCAR-G79 T cells)

Relapsed/Refractory Autoimmune Diseases · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleMiltenyi Biomedicine GmbHPhase 2

MB-CART20.1 (MB-CART20.1)

Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma; Non-Hodgkin's Lymphoma · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleTechnische Universität DresdenPhase 1

BCMA directed CAR T-cells (MDC-CAR-BCMA001, MDC-CAR-BCMA001 (BCMA directed CAR T-cells))

Neoplasms; Relapsed Diffuse Large B-cell Lymphoma (DLBCL) · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleNkarta, Inc.Phase 1

NKX101 - CAR NK cell therapy (NKX101 - CAR NK cell therapy)

Relapsed/Refractory AML; AML, Adult · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleHadassah Medical OrganizationPhase 1

Naive HBI0101 CAR-T (Naive HBI0101 CAR-T)

Relapsed/Refractory Multiple Myeloma (MM) · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleBeijing GoBroad HospitalPhase 1

Newly matched donor-derived FL-33 CAR T therapy (Newly matched donor-derived FL-33 CAR T therapy)

Refractory/Relapsed Acute Myeloid Leukaemia · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
AntibodyLimited DatastaleRochePhase 2

Orelabrutinib and Rituximab (Orelabrutinib and Rituximab)

Follicular Lymphoma; Relapsed and Refractory Follicular Lymphoma · FRα

#FR#Antibody#Phase2#monoclonal-antibody#FollicularLymphoma+2
Trials 1Status Recruiting
CGTLimited DatastalePrecision BioSciences, Inc.Phase 2

PBCAR20A (PBCAR20A)

Non-Hodgkin's Lymphoma, Relapsed; Chronic Lymphoid Leukemia in Relapse · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 1Status Active

6 / 7 pages

← PreviousNext →